Eyecare giant Alcon has bought a majority stake in cell therapy start-up Aurion Biotech, replacing the company's chief executive, in the culmination of a months-long struggle for control. In a ...
Leverages Alcon's global scale with Aurion's cell therapy expertise to accelerate US Phase 3 development in fall of 2025 Alcon, the global leader in eye care, has acquired a majority interest in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results